Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

A randomized, placebo-controlled, double-blinded trial of MRSA throat carriage treatment, with either standard decolonization alone or in combination with oral clindamycin

Research output: Contribution to journalJournal articlepeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{7dcf930c33534a26877c680c95a52f29,
title = "A randomized, placebo-controlled, double-blinded trial of MRSA throat carriage treatment, with either standard decolonization alone or in combination with oral clindamycin",
abstract = "BACKGROUND: Staphylococcus aureus is a frequent colonizer of the human skin and mucous membranes but can also cause a variety of serious infections. Antimicrobial resistance is an increasing worldwide challenge and is mainly driven by an overuse of antimicrobials. To avoid the spread of methicillin-resistant Staphylococcus aureus (MRSA) in Denmark, the Danish Health Authority recommends decolonization treatment of MRSA carriers and their household contacts. Standard decolonization treatment includes chlorhexidine body wash and mupirocin nasal ointment, especially throat carriage is difficult to treat. The broad-spectrum antibiotic, clindamycin, is often added to the decolonization treatment, but there is currently low scientific evidence for this treatment.AIM: To investigate whether the addition of clindamycin to the standard decolonization treatment increases decolonization success in MRSA throat carriers.METHODS: A randomized, placebo-controlled, double-blinded trial, including patients ≥ 18 years, who tested MRSA positive in the throat after completing one standard decolonization treatment. All carriers included in the trial receive standard decolonization treatment and are randomized to treatment with either placebo or clindamycin capsules for 10 days. We plan to include 40 participants in each of the two treatment arms.DISCUSSION: Due to the lack of consistent scientific evidence of clindamycin's effect in MRSA decolonization and the worldwide urgent need to reduce the use of antibiotics, we judged that a 30% increase in the decolonization success rate in carriers treated with clindamycin is appropriate to justify prescribing clindamycin as part of the decolonization treatment of asymptomatic MRSA carriers.TRIAL REGISTRATION: EudraCT number 2019-002631-29.",
keywords = "Anti-Bacterial Agents/adverse effects, Anti-Infective Agents, Local, Chlorhexidine, Clindamycin/adverse effects, Humans, Methicillin-Resistant Staphylococcus aureus, Mupirocin/adverse effects, Pharynx, Staphylococcal Infections/diagnosis, Methicillin-resistant Staphylococcus aureus, Treatment failure, MRSA eradication, MRSA decolonization, MRSA throat carriage",
author = "Holm, {Mona Katrine Alberthe} and Meiniche, {Heidi Karin} and Michael Pedersen and Eriksen, {Helle Brander} and Henrik Westh and Holzknecht, {Barbara J} and Bartels, {Mette Damkj{\ae}r}",
note = "{\textcopyright} 2022. The Author(s).",
year = "2022",
month = jun,
day = "16",
doi = "10.1186/s13063-022-06443-1",
language = "English",
volume = "23",
pages = "1--8",
journal = "Trials",
issn = "1745-6215",
publisher = "BioMed Central Ltd",
number = "1",

}

RIS

TY - JOUR

T1 - A randomized, placebo-controlled, double-blinded trial of MRSA throat carriage treatment, with either standard decolonization alone or in combination with oral clindamycin

AU - Holm, Mona Katrine Alberthe

AU - Meiniche, Heidi Karin

AU - Pedersen, Michael

AU - Eriksen, Helle Brander

AU - Westh, Henrik

AU - Holzknecht, Barbara J

AU - Bartels, Mette Damkjær

N1 - © 2022. The Author(s).

PY - 2022/6/16

Y1 - 2022/6/16

N2 - BACKGROUND: Staphylococcus aureus is a frequent colonizer of the human skin and mucous membranes but can also cause a variety of serious infections. Antimicrobial resistance is an increasing worldwide challenge and is mainly driven by an overuse of antimicrobials. To avoid the spread of methicillin-resistant Staphylococcus aureus (MRSA) in Denmark, the Danish Health Authority recommends decolonization treatment of MRSA carriers and their household contacts. Standard decolonization treatment includes chlorhexidine body wash and mupirocin nasal ointment, especially throat carriage is difficult to treat. The broad-spectrum antibiotic, clindamycin, is often added to the decolonization treatment, but there is currently low scientific evidence for this treatment.AIM: To investigate whether the addition of clindamycin to the standard decolonization treatment increases decolonization success in MRSA throat carriers.METHODS: A randomized, placebo-controlled, double-blinded trial, including patients ≥ 18 years, who tested MRSA positive in the throat after completing one standard decolonization treatment. All carriers included in the trial receive standard decolonization treatment and are randomized to treatment with either placebo or clindamycin capsules for 10 days. We plan to include 40 participants in each of the two treatment arms.DISCUSSION: Due to the lack of consistent scientific evidence of clindamycin's effect in MRSA decolonization and the worldwide urgent need to reduce the use of antibiotics, we judged that a 30% increase in the decolonization success rate in carriers treated with clindamycin is appropriate to justify prescribing clindamycin as part of the decolonization treatment of asymptomatic MRSA carriers.TRIAL REGISTRATION: EudraCT number 2019-002631-29.

AB - BACKGROUND: Staphylococcus aureus is a frequent colonizer of the human skin and mucous membranes but can also cause a variety of serious infections. Antimicrobial resistance is an increasing worldwide challenge and is mainly driven by an overuse of antimicrobials. To avoid the spread of methicillin-resistant Staphylococcus aureus (MRSA) in Denmark, the Danish Health Authority recommends decolonization treatment of MRSA carriers and their household contacts. Standard decolonization treatment includes chlorhexidine body wash and mupirocin nasal ointment, especially throat carriage is difficult to treat. The broad-spectrum antibiotic, clindamycin, is often added to the decolonization treatment, but there is currently low scientific evidence for this treatment.AIM: To investigate whether the addition of clindamycin to the standard decolonization treatment increases decolonization success in MRSA throat carriers.METHODS: A randomized, placebo-controlled, double-blinded trial, including patients ≥ 18 years, who tested MRSA positive in the throat after completing one standard decolonization treatment. All carriers included in the trial receive standard decolonization treatment and are randomized to treatment with either placebo or clindamycin capsules for 10 days. We plan to include 40 participants in each of the two treatment arms.DISCUSSION: Due to the lack of consistent scientific evidence of clindamycin's effect in MRSA decolonization and the worldwide urgent need to reduce the use of antibiotics, we judged that a 30% increase in the decolonization success rate in carriers treated with clindamycin is appropriate to justify prescribing clindamycin as part of the decolonization treatment of asymptomatic MRSA carriers.TRIAL REGISTRATION: EudraCT number 2019-002631-29.

KW - Anti-Bacterial Agents/adverse effects

KW - Anti-Infective Agents, Local

KW - Chlorhexidine

KW - Clindamycin/adverse effects

KW - Humans

KW - Methicillin-Resistant Staphylococcus aureus

KW - Mupirocin/adverse effects

KW - Pharynx

KW - Staphylococcal Infections/diagnosis

KW - Methicillin-resistant Staphylococcus aureus

KW - Treatment failure

KW - MRSA eradication

KW - MRSA decolonization

KW - MRSA throat carriage

UR - http://www.scopus.com/inward/record.url?scp=85132079589&partnerID=8YFLogxK

U2 - 10.1186/s13063-022-06443-1

DO - 10.1186/s13063-022-06443-1

M3 - Journal article

C2 - 35710440

VL - 23

SP - 1

EP - 8

JO - Trials

JF - Trials

SN - 1745-6215

IS - 1

M1 - 502

ER -

ID: 78937854